CNSX:ZRO

Stock Analysis Report

Executive Summary

Biosenta Inc. develops and deploys a range of anti-microbial products and remediation solutions for commercial and consumer applications.

Snowflake

Fundamentals

Overvalued with worrying balance sheet.

Risks

  • Biosenta's last earnings update was 247 days ago.
  • Biosenta is not covered by any analysts.

Share Price & News

How has Biosenta's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

CNSX:ZRO

-1.6%

CA Household Products

-0.9%

CA Market


1 Year Return

100.0%

CNSX:ZRO

34.3%

CA Household Products

-6.1%

CA Market

ZRO outperformed the Household Products industry which returned 43.8% over the past year.

ZRO outperformed the Market in Canada which returned 3% over the past year.


Share holder returns

ZROIndustryMarket
7 Day0%-1.6%-0.9%
30 Day0%3.3%-3.4%
90 Dayn/a8.7%-3.1%
1 Year100.0%100.0%38.2%34.3%-2.8%-6.1%
3 Year-6.7%-6.7%44.1%31.8%13.2%3.1%
5 Yearn/a69.4%45.5%10.8%-4.7%

Price Volatility Vs. Market

How volatile is Biosenta's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biosenta undervalued based on future cash flows and its price relative to the stock market?

1.52x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Biosenta to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Biosenta to establish if it is available at substantial discount.


Price Based on Earnings

Biosenta is loss making, we can't compare its value to the North America Household Products industry average.

Biosenta is loss making, we can't compare the value of its earnings to the Canada market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Biosenta, we can't assess if its growth is good value.


Price Based on Value of Assets

Biosenta is good value based on assets compared to the North America Household Products industry average.


Next Steps

Future Growth

How is Biosenta expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.7%

Forecasted Household industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biosenta has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Biosenta performed over the past 5 years?

37.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Biosenta does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Biosenta's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Biosenta's 1-year growth to the North America Household Products industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Biosenta has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Biosenta has efficiently used its assets last year compared to the North America Household Products industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Biosenta improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Biosenta's financial position?


Financial Position Analysis

Biosenta's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Biosenta's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Biosenta's level of debt (34.2%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 34.2% today).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Biosenta has less than a year of cash runway based on current free cash flow.

Biosenta has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.8% each year.


Next Steps

Dividend

What is Biosenta's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Biosenta's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Biosenta's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Biosenta has not reported any payouts.

Unable to verify if Biosenta's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Biosenta has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Biosenta's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average board tenure


CEO

Dene Rogers (57yo)

4.6yrs

Tenure

CA$109,354

Compensation

Mr. Dene L. Rogers has been the President and Chief Executive Officer of General Wireless Operations Inc., since May 9, 2016. Mr. Rogers serves as the Chief Executive Officer and President of Biosenta Inc. ...


CEO Compensation Analysis

Dene's remuneration is lower than average for companies of similar size in Canada.

Dene's compensation has been consistent with company performance over the past year.


Board Age and Tenure

4.3yrs

Average Tenure

The tenure for the Biosenta board of directors is about average.


Insider Trading

No 3 month insider trading information.


Ownership Breakdown


Management Team

  • Dene Rogers (57yo)

    Interim Chairman

    • Tenure: 4.6yrs
    • Compensation: CA$109.35k
  • Louis Nagy

    Consultant

    • Tenure: 0.0yrs
    • Compensation: CA$25.43k

Board Members

  • Dene Rogers (57yo)

    Interim Chairman

    • Tenure: 4.6yrs
    • Compensation: CA$109.35k
  • Nick Iacono

    Independent Director

    • Tenure: 2.5yrs
  • Ed Korhonen (83yo)

    Independent Director

    • Tenure: 10.9yrs
    • Compensation: CA$9.75k
  • David Butler

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: CA$9.75k
  • Am Gill

    Independent Director

    • Tenure: 2.5yrs

Company Information

Biosenta Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biosenta Inc.
  • Ticker: ZRO
  • Exchange: CNSX
  • Founded:
  • Industry: Household Products
  • Sector: Household
  • Market Cap: CA$984.386k
  • Shares outstanding: 14.06m
  • Website: https://www.biosenta.com

Location

  • Biosenta Inc.
  • 18 Wynford Drive
  • Unit 704
  • Toronto
  • Ontario
  • M3C 3S2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZROCNSX (Canadian National Stock Exchange)YesClass A SharesCACADOct 2015

Biography

Biosenta Inc. develops and deploys a range of anti-microbial products and remediation solutions for commercial and consumer applications. The company offers household disinfectants and cleaners to kill dea ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/05/03 02:59
End of Day Share Price2019/02/04 00:00
Earnings2018/06/30
Annual Earnings2017/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.